ArticleInternational journal of nanomedicine2025
Synthesis of Mesoporous Polydopamine-Coated Upconversion Nanoparticles for Dual-Enhanced Photodynamic and Photothermal Cancer Therapy.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Surface bioengineering of lanthanide nanoparticles for theranostic applications: From hydrophilic modification to multimodal imaging and therapy.Materials today. Bio · 2026Review
- Natural Product-Based Upconversion-Downshifting Photosensitizers in Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Fabrication of cercosporin-loaded polydopamine- cloaked mesoporous silica nanoparticles enhanced photothermal-photodynamic and anticancer activity in pancreatic cancer.Journal of materials science. Materials in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Photodynamic therapy (PDT) is a common cancer treatment strategy that combines the use of light, a photosensitizer, and oxygen to precisely generate reactive oxygen species (ROS). However, the efficacy of this method is limited by the shallow tissue penetration of the short-wavelength lasers involved, and combination therapy with other treatments such as photothermal therapy (PTT) or radiation therapy requires additional lasers or instruments. A new dual therapy approach using a single laser could minimize the treatment procedure. Methods: Chlorin e6 (Ce6) loaded-NaYF Results and Discussion: The PDT-PTT UCNPs were successfully synthesized and emit photoluminescence spectra that can be absorbed by Ce6 to induce the PDT effect. Significant ROS generation was observed from U@MSC@MP NPs following 808 nm laser irradiation for 5 min, which corresponded to intracellular ROS detection in human colorectal adenocarcinoma HT-29 cells. The NPs significantly reduced HT-29 cell viability compared with PDT or PTT alone, demonstrating the potential of the designed UCNPs. Moreover, the in vivo antitumor efficacy analysis confirmed the dual effect with no signs of toxicity, supporting the safety and biocompatibility of the synthesized NPs. Conclusion: These findings suggest that the combination of PDT and PTT using a single laser can be achieved with UCNPs. This approach is a promising strategy for simplifying the cancer treatment procedures in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.